Tokyo:4502

OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines

* The collaboration will develop an innovative genomic-based clinical treatment platform * The goal of the collaboration is to accelerate the R&D and commercialization of innovative medicines SHANGHAI, Nov. 11, 2020 /PRNewswire/ --OrigiMed, a China-based leading precision medicine company and...

2020-11-11 21:26 4392

Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate

Patients are advised to immediately consult their healthcare providers to help ensure safe discontinuation of NATPARA treatment Takeda is working closely with the US Food and Drug Administration (US FDA) to resolve the issue and resume supply as soon as possible OSAKA, Japan, Sept. 6, 2019 /PRNe...

2019-09-06 05:59 7327

Takeda, Microsoft and EURORDIS release report with action plan to help rare disease community shorten the diagnostic odyssey

Global Commission's recommendations focus on three solution pathways that leverage technology toaddress key elements of the rare disease diagnostic odyssey Rare diseases remain undiagnosed as patients struggle to navigate complex health systems to receive accurate diagnoses, which can take an av...

2019-02-20 19:07 1480

New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients

OSAKA, Japan, Oct. 16, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502), ("Takeda") today announced the presentation of data suggesting early symptomatic improvement in specific symptoms with Entyvio® (vedolizumab) in patients with moderately to severely active ulcerative co...

2017-10-16 20:16 345

Takeda and Marvel Custom Solutions Debut the Full IBD Unmasked Graphic Novel Featuring a Team of Inflammatory Bowel Disease (IBD) Super Heroes

Two new chapters complete The Unbeatables graphic novel designed to raise awareness of the unrecognized Super Heroes of the global IBD community OSAKA, Japan, Aug. 2, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited[TSE: 4502] , with the sup...

2017-08-02 16:30 2974

Takeda and Marvel Custom Solutions Launch the Latest Adventure of the IBD Unmasked Super Hero Squad in Celebration of World IBD Day 2017

New chapter of The Unbeatables graphic comic book highlights the strength of those living with inflammatory bowel disease (IBD) OSAKA, Japan, May 19, 2017 /PRNewswire/ -- In celebration of World IBD Day, which takes place every year on 19 May, Takeda Pharmaceutical Company Limited [ TSE: 4502

2017-05-19 14:11 4444

New Real-World Analyses Support Effectiveness and Safety of Entyvio(R) (vedolizumab) for Ulcerative Colitis and Crohn's Disease

OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the presentation of eight real-world analyses supporting the effectiveness and safety of Entyvio® (vedolizumab) for the treatment of adults with moderately to severely active ul...

2017-05-08 23:08 2341

Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease

Post-hoc data from GEMINI I also presented at ECCO further support a favorable benefit: risk profile for vedolizumab as a treatment option for adult patients with moderate to severely active ulcerative colitis to maintain sustained remission OSAKA, Japan, Feb. 17, 2017 /PRNewswire/ -- Takeda Pha...

2017-02-17 20:13 3669

GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab

OSAKA, Japan, Dec. 9, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that an analysis based on pre-specified and post-hoc exploratory outcomes of GEMINI II and GEMINI III data evaluating Entyvio (vedolizumab) therapy in patients with moderately to se...

2016-12-09 23:18 2153

Takeda Unmasks Four New Super Heroes at London's Comic Con to Highlight the Strength of those Living with Inflammatory Bowel Disease (IBD) with the Support of Marvel Custom Solutions

OSAKA, Japan, Oct. 28, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502 ) along with the support of Marvel Custom Solutions today announces the launch of four new Super Hero characters and the first chapter of a new graphic comic...

2016-10-28 16:05 2299

Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies

OSAKA, Japan, Oct. 17, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") is presenting data on the real-world effectiveness and safety of vedolizumab in patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) during the United ...

2016-10-17 14:00 1937

Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis

OSAKA, Japan, Sept. 29, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited[TSE: 4502] , ("Takeda") announced that two interim reports from the ongoing, open-label GEMINI long-term safety (LTS) study describing clinical data of long-term Entyvi...

2016-09-29 03:49 1735

Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology

OSAKA, Japan, Sept. 18, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited[TSE: 4502], ("Takeda") announced that an exploratory analysis of the GEMINI 1 data, evaluating Entyvio (vedolizumab) therapy in patients with ulcerative colitis (UC) ba...

2016-09-18 10:54 1437

Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

OSAKA, Japan and LEUVEN, Belgium, Aug. 2, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502 ) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the 24-week results of the Phase 3 ADMIRE-CD trial inv...

2016-08-02 15:19 2149

IBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community

OSAKA, Japan, July 13, 2016 /PRNewswire/ -- Takeda unveils new IBD   S uper   H ero and graphic illustrations, developed in collaboration with Marvel Custom Solutions, to highlight the strength of and inspire confidence in those living with IBD    If someone with inflammatory bowel disease (...

2016-07-13 16:55 1913

Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

OSAKA, Japan and LEUVEN, Belgium, July 5, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502 ) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the companies have entered into an exclusive ex-U.S. ...

2016-07-05 14:14 2526

EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care

OSAKA, Japan, June 12, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502 ], ("Takeda") announced the publication of a post-hoc analysis from the global EXAMINE (EX amination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE...

2016-06-12 11:10 1754

Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders

OSAKA, Japan and DUBLIN, June 8, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced that the companies have entered into a global license, development and commercialization agreem...

2016-06-08 21:02 2371

Takeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions

OSAKA, Japan, June 7, 2016 /PRNewswire/ -- Takeda Pharmaceuticals Company Limited[TSE: 4502], ("Takeda") will present eight abstracts at the American Diabetes Association's 76th Scientific Sessions, which takes place inNew Orleans, LA, on June 10-14, ...

2016-06-07 01:09 1730

Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting

OSAKA, Japan, May 24, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502 ], ("Takeda") today announced the oral presentations of two data analyses: one evaluating the optimal position of vedolizumab in the ulcerative colitis (UC) tre...

2016-05-24 00:56 2107
12